So Kent Chak-Yu, Xu Jianqiang, Kam Kevin Ka-Ho, Sung Shih-Hsien, Meemook Krissada, Wang Dee Dee, Tang Gilbert H L, Lee Alex Pui-Wai, Lam Yat-Yin
Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China.
Department of Cardiology, Tianjin First Central Hospital, Tianjin, China.
JACC Asia. 2025 Mar;5(3 Pt 2):405-423. doi: 10.1016/j.jacasi.2024.10.008. Epub 2024 Dec 17.
Transcatheter tricuspid interventions are becoming increasingly more common in Asia Pacific. In the past decade, clinicians in Asia Pacific have worked with a multitude of new transcatheter tricuspid technologies. A standardized clinical algorithm to diagnose symptomatic tricuspid regurgitation to increase patient access to novel right heart therapies has not yet been identified. Anatomic diversity in the Asia Pacific patient population; disease prevalence patterns; and socioeconomic, cultural, and local health structures represent unique challenges in the treatment of these patients with right heart failure. As advancements are made in right heart failure and transcatheter tricuspid technologies, hopefully more patients can be treated not just in Asia Pacific, but across the entire world.
经导管三尖瓣干预在亚太地区正变得越来越普遍。在过去十年中,亚太地区的临床医生已使用了多种新型经导管三尖瓣技术。目前尚未确定一种标准化的临床算法来诊断症状性三尖瓣反流,以增加患者获得新型右心治疗的机会。亚太地区患者人群的解剖学多样性、疾病流行模式以及社会经济、文化和当地卫生结构,对这些右心衰竭患者的治疗构成了独特挑战。随着右心衰竭和经导管三尖瓣技术的进步,有望不仅在亚太地区,而且在全世界让更多患者得到治疗。